Leading RNA Technologies for Innovative Therapeutics

At AVI BioPharma we are focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. By leveraging our highly differentiated RNA-based technology platform, we have built a pipeline of potentially transformative therapeutic agents, including a clinical stage Duchenne muscular dystrophy candidate and anti-infective candidates for influenza and hemorrhagic fever viruses.

By applying pioneering technologies developed and optimized by AVI, we are able to target a broad range of diseases and disorders through distinct RNA-based mechanisms of action. Unlike siRNA, and other RNA-based approaches, our technologies can be used to directly target both messenger RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either down-regulate (inhibit) or up-regulate (promote) the expression of targeted genes or proteins.

This page was last updated on June 27, 2011.